• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 感染与 X 连锁严重联合免疫缺陷婴儿肝炎相关。

SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency.

机构信息

Department of Immunology, The University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-9093, United States of America; Department of Pediatrics, The University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-9093, United States of America; Department of Microbiology, The University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-9093, United States of America.

Department of Pediatrics, The University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-9093, United States of America.

出版信息

Clin Immunol. 2021 Mar;224:108662. doi: 10.1016/j.clim.2020.108662. Epub 2021 Jan 4.

DOI:10.1016/j.clim.2020.108662
PMID:33412294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7834850/
Abstract

X-linked severe combined immunodeficiency (X-SCID) is a disorder of adaptive immunity caused by mutations in the IL-2 receptor common gamma chain gene resulting in deficiencies of T and natural killer cells, coupled with severe dysfunction in B cells. X-SCID is lethal without allogeneic stem cell transplant or gene therapy due to opportunistic infections. An infant with X-SCID became infected with SARS-CoV-2 while awaiting transplant. The patient developed severe hepatitis without the respiratory symptoms typical of COVID-19. He was treated with convalescent plasma, and thereafter was confirmed to have SARS-CoV-2 specific antibodies, as detected with a microfluidic antigen array. After resolution of the hepatitis, he received a haploidentical CD34 selected stem cell transplant, without conditioning, from his father who had recovered from COVID-19. SARS CoV-2 was detected via RT-PCR on nasopharyngeal swabs until 61 days post transplantation. He successfully engrafted donor T and NK cells, and continues to do well clinically.

摘要

X 连锁严重联合免疫缺陷症(X-SCID)是一种适应性免疫障碍,由 IL-2 受体共同γ链基因突变引起,导致 T 细胞和自然杀伤细胞缺陷,同时 B 细胞严重功能障碍。如果没有同种异体干细胞移植或基因治疗,X-SCID 会因机会性感染而致命。一名等待移植的 X-SCID 婴儿感染了 SARS-CoV-2。该患者出现严重肝炎,没有 COVID-19 的典型呼吸道症状。他接受了恢复期血浆治疗,此后通过微流控抗原阵列检测到 SARS-CoV-2 特异性抗体。肝炎缓解后,他从已从 COVID-19 中康复的父亲那里接受了未经预处理的 HLA 单倍体相合 CD34 选择的干细胞移植。通过鼻咽拭子的 RT-PCR 检测到 SARS-CoV-2 直至移植后 61 天。他成功植入了供体 T 和 NK 细胞,并且临床状况持续良好。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5445/7834850/533713754706/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5445/7834850/533713754706/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5445/7834850/533713754706/gr1_lrg.jpg

相似文献

1
SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency.SARS-CoV-2 感染与 X 连锁严重联合免疫缺陷婴儿肝炎相关。
Clin Immunol. 2021 Mar;224:108662. doi: 10.1016/j.clim.2020.108662. Epub 2021 Jan 4.
2
Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure.病例报告:严重联合免疫缺陷 (SCID) 伴移植物失功的患者病毒复制持续 8 周以上,恢复期血浆实现 SARS-CoV-2 病毒清除。
Front Immunol. 2021 May 3;12:645989. doi: 10.3389/fimmu.2021.645989. eCollection 2021.
3
SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation.COVID-19 恢复期血浆疗法在造血干细胞移植后儿科患者中的应用。
Transfus Apher Sci. 2021 Feb;60(1):102983. doi: 10.1016/j.transci.2020.102983. Epub 2020 Nov 1.
4
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体(RES-Q-HR):一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
5
Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report.特定 T 细胞反应指导 COVID-19 重症患者使用恢复期血浆治疗和体液免疫缺陷:一例报告。
BMC Infect Dis. 2022 Apr 11;22(1):362. doi: 10.1186/s12879-022-07323-4.
6
Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.新冠病毒感染的恢复期血浆疗法:来自严重急性呼吸综合征冠状病毒、中东呼吸综合征冠状病毒和甲型H1N1流感感染的经验教训
Acta Med Indones. 2021 Jan;53(1):86-95.
7
SARS-CoV-2-Related Acute Respiratory Distress Syndrome Uncovers a Patient with Severe Combined Immunodeficiency Disease.与严重急性呼吸综合征冠状病毒2相关的急性呼吸窘迫综合征揭示了一名患有重症联合免疫缺陷病的患者。
J Clin Immunol. 2021 Oct;41(7):1507-1510. doi: 10.1007/s10875-021-01063-x. Epub 2021 Jun 25.
8
Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.在 B 细胞耗竭患者中使用恢复期血浆成功治疗 COVID-19 感染可能会促进细胞免疫。
Eur J Immunol. 2021 Oct;51(10):2478-2484. doi: 10.1002/eji.202149277. Epub 2021 Sep 3.
9
COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study.COVID-19 与儿科癌症患者的治疗中断有关,但与短期死亡率无关:一项波兰全国性研究。
J Hematol Oncol. 2021 Oct 11;14(1):163. doi: 10.1186/s13045-021-01181-4.
10
Comparison of Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibodies' Binding Capacity Between Human Milk and Serum from Coronavirus Disease 2019-Recovered Women.比较 COVID-19 恢复期女性人乳与血清中 SARS-CoV-2 特异性抗体的结合能力。
Breastfeed Med. 2021 May;16(5):393-401. doi: 10.1089/bfm.2020.0381. Epub 2021 Apr 9.

引用本文的文献

1
Severity of SARS-CoV-2 infection in children with inborn errors of immunity (primary immunodeficiencies): a systematic review.患有先天性免疫缺陷(原发性免疫缺陷)儿童的新型冠状病毒2型感染严重程度:一项系统评价
Allergy Asthma Clin Immunol. 2023 Aug 9;19(1):69. doi: 10.1186/s13223-023-00831-1.
2
Inherited and acquired errors of type I interferon immunity govern susceptibility to COVID-19 and multisystem inflammatory syndrome in children.I 型干扰素免疫的遗传和获得性错误决定了 COVID-19 和儿童多系统炎症综合征的易感性。
J Allergy Clin Immunol. 2023 Apr;151(4):832-840. doi: 10.1016/j.jaci.2023.02.003. Epub 2023 Feb 24.
3

本文引用的文献

1
Coronavirus disease 2019 in patients with inborn errors of immunity: An international study.先天性免疫缺陷患者的 2019 年冠状病毒病:一项国际研究。
J Allergy Clin Immunol. 2021 Feb;147(2):520-531. doi: 10.1016/j.jaci.2020.09.010. Epub 2020 Sep 24.
2
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.COVID-19 危重症患者体内针对 I 型干扰素的自身抗体。
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4585. Epub 2020 Sep 24.
3
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.
COVID-19 恢复期血浆治疗免疫功能低下患者:系统评价和荟萃分析。
JAMA Netw Open. 2023 Jan 3;6(1):e2250647. doi: 10.1001/jamanetworkopen.2022.50647.
4
Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity.严重急性呼吸综合征冠状病毒 2 感染和 COVID-19 对先天性免疫缺陷病患者的影响。
J Allergy Clin Immunol. 2023 Apr;151(4):818-831. doi: 10.1016/j.jaci.2022.11.010. Epub 2022 Dec 13.
5
Translation suppression underlies the restrained COVID-19 mRNA vaccine response in the high-risk immunocompromised group.翻译抑制是高风险免疫功能低下人群中 COVID-19 mRNA 疫苗反应受到限制的原因。
Front Immunol. 2022 Oct 26;13:1020165. doi: 10.3389/fimmu.2022.1020165. eCollection 2022.
6
COVID-19 mortality in patients with immunodeficiency and its predictors: a systematic review.免疫缺陷患者 COVID-19 死亡率及其预测因素:系统评价。
Eur J Med Res. 2022 Oct 8;27(1):195. doi: 10.1186/s40001-022-00824-7.
7
COVID-19-related health outcomes in people with primary immunodeficiency: A systematic review.原发性免疫缺陷患者的 COVID-19 相关健康结局:系统评价。
Clin Immunol. 2022 Oct;243:109097. doi: 10.1016/j.clim.2022.109097. Epub 2022 Aug 13.
8
COVID-19 and Inborn Errors of Immunity.COVID-19 与先天性免疫缺陷
Physiology (Bethesda). 2022 Nov 1;37(6):0. doi: 10.1152/physiol.00016.2022. Epub 2022 Aug 9.
9
COVID-19 GPH: tracking the contribution of genomics and precision health to the COVID-19 pandemic response.COVID-19 GPH:追踪基因组学和精准健康对 COVID-19 大流行应对的贡献。
BMC Infect Dis. 2022 Apr 25;22(1):402. doi: 10.1186/s12879-022-07219-3.
10
Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy.病例报告:CD19 CAR T 细胞治疗后,B 细胞缺陷患者接受恢复期血浆治疗诱导抗 SARS-CoV-2 T 细胞扩增、NK 细胞成熟和病毒清除
Front Immunol. 2021 Aug 12;12:721738. doi: 10.3389/fimmu.2021.721738. eCollection 2021.
COVID-19 危重症患者的 I 型 IFN 免疫先天缺陷。
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4570. Epub 2020 Sep 24.
4
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins.目前的静脉注射免疫球蛋白对 SARS-CoV-2 具有交叉中和活性。
Immunotherapy. 2020 Dec;12(17):1247-1255. doi: 10.2217/imt-2020-0220. Epub 2020 Sep 8.
5
COVID-19 and multisystem inflammatory syndrome in children and adolescents.儿童和青少年的 COVID-19 和多系统炎症综合征。
Lancet Infect Dis. 2020 Nov;20(11):e276-e288. doi: 10.1016/S1473-3099(20)30651-4. Epub 2020 Aug 17.
6
In-depth virological assessment of kidney transplant recipients with COVID-19.深度评估 COVID-19 肾移植受者的病毒学情况。
Am J Transplant. 2020 Nov;20(11):3162-3172. doi: 10.1111/ajt.16251. Epub 2020 Sep 12.
7
Longitudinal analyses reveal immunological misfiring in severe COVID-19.纵向分析揭示了重症 COVID-19 中的免疫失调。
Nature. 2020 Aug;584(7821):463-469. doi: 10.1038/s41586-020-2588-y. Epub 2020 Jul 27.
8
A male infant with COVID-19 in the context of ARPC1B deficiency.一名患有新冠病毒肺炎且存在ARPC1B缺陷的男婴。
Pediatr Allergy Immunol. 2021 Jan;32(1):199-201. doi: 10.1111/pai.13322. Epub 2020 Sep 2.
9
Duration of Respiratory and Gastrointestinal Viral Shedding in Children With SARS-CoV-2: A Systematic Review and Synthesis of Data.儿童 SARS-CoV-2 呼吸道和胃肠道病毒脱落持续时间:系统评价和数据综合。
Pediatr Infect Dis J. 2020 Sep;39(9):e249-e256. doi: 10.1097/INF.0000000000002814.
10
COVID-19 and the liver.COVID-19 与肝脏。
J Hepatol. 2020 Nov;73(5):1231-1240. doi: 10.1016/j.jhep.2020.06.006. Epub 2020 Jun 15.